Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | LIPA | P38571 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819872 | 0.87 | MGAT2 (0.37) | CYP3A4MGAT2HSD11B1LIPACYP2D6 | |
| SCHEMBL10221907 | 0.87 | MGAT2 (0.37) | CYP3A4MGAT2HSD11B1LIPACYP2D6 | |
| SCHEMBL4762461 | 0.82 | HSD11B1 (0.37) | MGAT2HSD11B1CYP2D6KCNH2HRH3 | |
| SCHEMBL17113908 | 0.80 | ACHE (0.42) | CYP3A4HRH3TSHRNPSR1HTT | |
| SCHEMBL24926136 | 0.78 | HSD11B1 (0.35) | MGAT2HSD11B1CYP2D6KCNH2HRH3 | |
| SCHEMBL18199688 | 0.78 | HSD11B1 (0.39) | CYP3A4MGAT2HSD11B1CYP2D6KCNH2 | |
| SCHEMBL27976164 | 0.78 | CYP3A4 (0.37) | CYP3A4HTR4WNT1GSK3BDYRK1A | |
| SCHEMBL17096046 | 0.78 | GNAI3 (0.41) | CYP3A4HTR4WNT1GSK3BDYRK1A | |
| SCHEMBL20118722 | 0.78 | CYP3A4 (0.37) | CYP3A4HTR4WNT1GSK3BDYRK1A | |
| SCHEMBL19786456 | 0.77 | HSD11B1 (0.33) | MGAT2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-07-24 | — | — | US | disclosed |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-07-24 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-07-10 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (CN) | 2018-01-18 | — | — | US | disclosed |
| US-9868737-B2 | Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitor | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-16 | — | — | US | disclosed |
| US-20180009820-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEREOF IN PREPARATION OF MEDICAMENT | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-08-24 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016270-A1 | DIAZA-BENZOFLUORANTHRENE COMPOUNDS | DDT, CYP3A43, CYP19A1 | CYP3A4 21/4885MGAT2 1998/4885HSD11B1 927/4885 |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | CYP3A4 276/4885MGAT2 2774/4885HSD11B1 479/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | CYP3A4 177/4885MGAT2 1686/4885HSD11B1 2971/4885 |
| US-20170240519-A1 | BENZOFURAN ANALOGUE AS NS4B INHIBITOR | GTF3C4, BRD4, CUL4B | CYP3A4 33/4885MGAT2 2341/4885HSD11B1 628/4885 |
| US-20170029430-A1 | ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS | PARP1, PARP2, PARP11 | CYP3A4 824/4885MGAT2 3995/4885HSD11B1 1940/4885 |
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | CYP3A4 1152/4885MGAT2 3632/4885HSD11B1 2945/4885 |
| US-20160318943-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEROF IN PREPARATION OF MEDICAMENT | MAVS, SARS1, IRF3 | CYP3A4 1270/4885MGAT2 2986/4885HSD11B1 4539/4885 |
| US-20180009820-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEREOF IN PREPARATION OF MEDICAMENT | MAVS, ZC3HAV1, SARS1 | CYP3A4 536/4885MGAT2 2298/4885HSD11B1 3046/4885 |
| US-10017507-B2 | Diaza-benzofluoranthrene compounds | DDT, CYP3A43, CYP19A1 | CYP3A4 21/4885MGAT2 1998/4885HSD11B1 927/4885 |
| US-10030029-B2 | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament | MAVS, ZC3HAV1, SARS1 | CYP3A4 536/4885MGAT2 2298/4885HSD11B1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.